DRG 374 Overview

DRG 374 covers hospital admissions for digestive system malignancies when a Major Complication or Comorbidity is present, typically including primary cancers of the esophagus, stomach, small intestine, colon, rectum, liver, pancreas, and biliary tract with significant additional acute problems. This Diagnosis-Related Group aggregates cases with higher resource use due to the malignant diagnosis plus severe comorbid conditions or complications that increase length of stay and intensity of services. It matters for Medicare payment because the presence of a Major Complication or Comorbidity shifts cases into a higher-weighted payment category under the Medicare Severity Diagnosis-Related Group framework. Accurate clinical documentation and coding of both the malignancy and the accompanying Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group and therefore influence inpatient reimbursement.

• Acute perioperative and peri-procedural intervention trials focusing on patients with advanced digestive tract cancers complicated by significant comorbidities or acute complications (for example, studies evaluating optimized perioperative care bundles, enhanced recovery protocols, or blood-conservation strategies in patients undergoing resection for colorectal, gastric, or hepatobiliary malignancies). These trials enroll inpatients who present for major oncologic surgery or emergency procedures and examine short-term outcomes such as complication rates, intensive care utilization, length of stay, and 30-day readmission; findings inform clinical pathways that can reduce severe complications and high-cost resource use common in this DRG. This research is highly relevant to providers and payers because improvements in perioperative management can lower mortality and expensive downstream care associated with major digestive malignancy complications and MCCs (major complications or comorbidities).
• Comparative effectiveness studies of systemic and multimodality treatment strategies in hospitalized patients with advanced digestive malignancies and complex comorbidity profiles, including trials that compare sequencing of chemotherapy, targeted agents, or locoregional therapies (e.g., hepatic-directed therapies) in patients who require inpatient initiation or management. These studies target real-world inpatient populations that often have organ dysfunction, prior treatment exposure, or frailty, and aim to measure outcomes such as inpatient resource utilization, treatment-related severe adverse events, and short-term survival to guide choice of therapy in high-risk patients. Payers and health systems use this evidence to refine coverage policies and care pathways that balance clinical benefit with the high costs and toxicity risks seen in medically complex inpatients captured by this DRG.
• Post-discharge outcomes and care-coordination trials examining transitions from hospital to home or skilled nursing for patients with digestive malignancy and major comorbidities, including randomized or pragmatic studies of intensive discharge planning, palliative care integration, or remote monitoring to prevent readmissions and manage symptom burden. These trials enroll patients at discharge after an inpatient stay for malignant digestive disease with MCC and track metrics such as 90-day readmission, emergency visits, symptom control, and end-of-life care alignment. For providers and payers, evidence from these studies supports interventions that reduce avoidable readmissions and high-cost episodic care while improving quality of life and appropriate utilization for a population at high risk of recurrent inpatient needs.